The authors of AMNOG, Germany's
new drug pricing law, evidently didn't consider what to do when a drug shows
benefit in some patient subgroups but not in others. These drugs, which are rapidly
becoming the norm, don't fit into either of the scheme's two categories:
premium priced or reference priced.
Hints about how Germany will handle the pricing of so-called
mixed-benefit drugs could come in the next six months, when AstraZeneca
plc wraps up its pricing negotiations for Brilique ticagrelor to
prevent atherothrombotic events in acute coronary syndrome (ACS) patients.